Core Viewpoint - Fermi Inc. is facing a class action lawsuit due to allegations of securities fraud related to its Project Matador campus, with significant implications for investors who purchased shares during the specified class period [3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Fermi securities between September 28, 2025, and December 11, 2025, alleging that the company overstated tenant demand for its Project Matador campus [3]. - Allegations include the reliance on a single tenant's funding commitment for financing the construction of Project Matador and the risk of that tenant terminating its funding commitment [3]. - Fermi's share price dropped significantly after the announcement that the first tenant had terminated a $150 million funding agreement, leading to a decline of approximately 33.8% from $15.25 to $10.09 per share [4]. Group 2: Investor Actions - Investors who suffered losses on their Fermi investments have until March 6, 2026, to request lead plaintiff appointment, which is crucial for overseeing the litigation [2]. - Individual investors can be appointed as lead plaintiffs, influencing key decisions in the lawsuit [2]. - Interested parties are encouraged to contact Kirby McInerney LLP for more information regarding their rights and interests in the lawsuit [5].

Core Viewpoint - Grabar Law Office is investigating claims on behalf of shareholders of Molina Healthcare, Inc. regarding potential breaches of fiduciary duties by certain officers and directors [1] Group 1: Investigation Details - The investigation focuses on whether Molina Healthcare's officers and directors failed to disclose material adverse facts related to the company's financial health [3] - Allegations include a failure to disclose issues with "medical cost trend assumptions" and a "dislocation between premium rates and medical cost" [3] - It is claimed that Molina Healthcare's near-term growth relies on a lack of utilization of various health services, which may lead to a significant cut in financial guidance for fiscal year 2025 [3] Group 2: Shareholder Actions - Shareholders who purchased Molina Healthcare shares prior to February 5, 2025, and still hold them can seek corporate reforms and the return of funds at no cost [2][4] - Interested shareholders are encouraged to contact Grabar Law Office for more information on the investigation and potential actions [2][4]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Cogent Communications Holdings, Inc. and its officers or directors [1] Financial Performance - On November 6, 2025, Cogent reported a year-over-year service revenue decline of nearly 6% for the third quarter of 2025 [3] - The company announced a significant dividend cut of 98%, reducing it from $1.015 per share to $0.02 per share [3] - Following the announcement, Cogent's stock price dropped by $13.35 per share, or 34.86%, closing at $24.95 per share on the same day [3]

LOS ANGELES, Jan. 20, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Ardent Health, Inc. ("Ardent" or the "Company") (NYSE: ARDT) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ARDENT HEALTH, INC. (ARDT), CLICK HERE BEFORE MARCH 9, 2026 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. What Is The Lawsuit About? The complaint filed alleges that, betwe ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of PDD Holdings Inc. ("PDD†or the "Company†) (NASDAQ: PDD) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON PDD HOLDINGS INC. (PDD), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On January 19, 2026, Bloomberg reported that China had broadened its probe. ...

Core Viewpoint - A class action lawsuit has been filed against Smart Digital Group Limited, alleging securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves claims that Smart Digital and certain officers and/or directors engaged in securities fraud [2]. - Investors have until March 16, 2026, to request appointment as Lead Plaintiff if they purchased Smart Digital securities during the Class Period [2]. Group 2: Stock Price and SEC Actions - On September 26, 2025, Smart Digital's stock price dropped 86.4% to close at $1.85 per share after a trading halt by NASDAQ due to volatility [4]. - The SEC suspended trading in Smart Digital securities from September 29, 2025, to October 10, 2025, due to potential manipulation linked to social media recommendations [4]. - Following the SEC suspension, NASDAQ also suspended trading in Smart Digital securities pending further information on October 11, 2025 [4]. Group 3: Pomerantz LLP Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for class members [5].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Smart Digital Group Limited (SDM) on behalf of investors who acquired its securities during the specified class period, alleging misleading statements and failure to disclose material adverse facts about the company's operations and prospects [1][4]. Group 1: Lawsuit Details - The lawsuit claims that during the class period, SDM made materially false and misleading statements and failed to disclose significant risks related to market manipulation and fraudulent promotion schemes [4]. - Allegations include that insiders used offshore accounts to facilitate share dumping during a price inflation campaign, and that SDM's public statements omitted risks of fraudulent trading [4]. - The lawsuit indicates that SDM securities were at risk of trading suspension by the SEC and NASDAQ due to these undisclosed risks [4]. Group 2: Trading Activity and SEC Involvement - On September 26, 2025, NASDAQ temporarily halted trading of SDM stock due to volatility, with over 270,000 orders placed in a single minute, leading to a stock price drop of 88% to $1.85 per share [2]. - The SEC announced a temporary suspension of trading in SDM from September 29, 2025, to October 25, 2025, due to potential manipulation through social media recommendations [3]. - Trading in SDM remains suspended as NASDAQ awaits additional information from the company [3].

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Bath & Body Works, Inc. (“Bath & Body Works” or the “Company”) (NYSE: BBWI).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Bath & Body ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Vanda Pharmaceuticals Inc. and its officers or directors, following a negative FDA decision regarding the approval of HETLIOZ for jet lag disorder [1][3]. Group 1: FDA Decision and Market Reaction - On January 8, 2026, Vanda announced that the FDA concluded the supplemental New Drug Application for HETLIOZ could not be approved in its current form, despite acknowledging positive efficacy from clinical trials [3]. - The FDA's decision was based on the view that the clinical trial protocols did not adequately simulate actual jet travel conditions, which involve additional factors such as reduced oxygen pressure and environmental changes [3]. - Following the announcement, Vanda's stock price dropped by $1.20 per share, a decline of 14.05%, closing at $7.34 per share on the same day [3]. Group 2: Legal Investigation - Pomerantz LLP is actively investigating claims on behalf of Vanda's investors, suggesting potential legal action related to the company's business practices [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2][6]. Group 3: Pomerantz LLP Overview - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud and corporate misconduct [4]. - The firm has been involved in the field of securities class actions for over 85 years, continuing the legacy of its founder, Abraham L. Pomerantz [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Teleflex Incorporated and its executives following the abrupt departure of CEO Liam Kelly, which led to a significant drop in the company's stock price [1][3]. Group 1: Company Developments - On January 8, 2026, Teleflex announced the immediate departure of Liam Kelly as Chairman, President, and CEO [3]. - Following this announcement, Teleflex's stock price decreased by $16.52 per share, representing a 13.06% decline, closing at $110.01 per share [3]. Group 2: Legal Investigation - Pomerantz LLP is representing investors in investigating claims against Teleflex regarding possible securities fraud or other unlawful business practices [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2].